Breast Tumor Scintigraphy

Journal of Nuclear Medicine Technology

Nanda Y. Khedkar¹  Patrick J. Peller¹  Charles J. Martinez¹ 

[1] Nuclear Medicine Division, Lutheran General Hospital, Park Ridge, Illinois Nuclear Medicine Division, Lutheran General Hospital, Park Ridge, Illinois Nuclear Medicine Division, Lutheran General Hospital, Park Ridge, Illinois

关键词: breast cancer;    technetium-99m-MIBI;    thallium-201;    fluorine-18-FDG;    breast imaging;   

DOI  :  

学科分类：医学（综合）

来源: Society of Nuclear Medicine

【 摘 要 】

Breast cancer is the most common and, probably, the most feared malignancy of American women today. Although screening with breast examination and mammography is extremely important in the early detection of breast cancer, the limited specificity of these techniques creates the need for an adjunctive diagnostic tool. Technetium-99m-sestamibi was originally developed as a myocardial perfusion agent but also preferentially accumulates intracellularly in metabolically active breast cancer tissue. Sestamibi breast imaging can delineate breast cancers and exclude the presence of a neoplastic process with high accuracy. Careful attention to imaging parameters provides high-quality breast tumor scintigraphy. Breast scintigraphy can be a valuable, adjunctive diagnostic tool in evaluating breast abnormalities.

【 授权许可】

Unknown